Results: 30-day survival rate was 89.6%+ 4.4%, and the 2-year survival rate was 82.2%+5.8%. By univariate analysis, age 65 years or older, rupture of the aneurysm (including those with aortoenteric fistula and aortobronchial fistula), and fever at the time of operation were identified as significant predictors of persistent infection.
Conclusions: EVAR seems a possible alternative method for treating mycotic aortic aneurysms. Identification of the risk factors for persistent infection may help to decrease surgical morbidity and mortality. EVAR could be used as a temporary measure; however, a definite surgical treatment should be considered for patients present with aneurysm rupture or fever. J Vasc Surg 2007; 46:906-12 Aortic-Enteric Fistula Outcome after endovascular stent graft repair of aortoenteric fistula: A systematic review George A. Antoniou, MD,a Stylianos Koutsias, MD,a Stavros A. Antoniou,a Andreas Georgiakakis, MD,a Miltos K. Lazarides, MD, EBSQvasc,b and Athanasios D. Giannoukas, MD, MSc, PhD, EBSQvasc,a Larissa and Alexandroupolis, Greece Results: Data were extracted from 33 reports that included 41 patients and were entered in the final analysis. Persistent/recurrent/new infection or recurrent hemorrhage developed in 44% of the patients, after a mean follow-up period of 13 months (range, 0.13-36). Secondary, as compared to primary, AEF had an almost threefold increased risk of persistent/recurrent infection. Evidence of sepsis preoperatively was found to be a factor indicating unfavorable outcome (P < .05). Persistent/recurrent/new infection after treatment was associated with worse 30-day and overall survival compared with those who did not develop sepsis (P < .05). In-hospital mortality after EV-AEFR < O-AEFR (0% and 35%, respectively, p = 0.13). Morbidity after EV-AEFR was lower compared to O-AEFR (25% and 77%,respectively, p= 0.028). There was a trend for worse recurrence-free, sepsis-free, re-operation-free and AEF-related death-free rates after EV-AEFR.
Early survival advantage of EV-AEFR was lost after two years and the overall long-term survival rates (perioperative mortality included) of the two groups were similar. Preoperative sepsis had no effect on recurrence and sepsis-free rates (p = 0.94 and p = 0.92, respectively), but it was associated with worse two year overall survival (24% vs 50%, p=0.32). On multivariate analysis, the number of symptoms (two vs one) at presentation was the single predictor of worse re-operation rates,AEF-related and overall survival.
Conclusions: EV-AEFR should serve as a bridging option in selected patients. Further trials should focus on 1. Role of EV-AEFR in patients at high risk for O-AEFR, due to shock or co-morbidities, or as a bridge therapy. 2. Investigate methods to eliminate sepsis in an effort to improve patient survival. 
Infected Endografts

Abstract
The prevalence of endograft infections (EI) after endovascular abdominal aortic aneurysm repair is below 1%. With the growing number of patients with aortic endografts and the aging population, the number of patients with EI might also increase. The diagnosis is based on an association of clinical symptoms, imaging, and microbial cultures. Angio-computed tomography is currently the gold-standard technique for diagnosis. Low-grade infection sometimes requires nuclear medicine imaging to make a correct diagnosis. There is no good evidence to guide management so far. In the case of active gastrointestinal bleeding, pseudoaneurysm, or extensive perigraft purulence involving adjacent organs, an invasive treatment should always be attempted. In the other cases (the majority), when there is not an immediate danger to the patient's life, a conservative management is started with a proper antimicrobial therapy. Any infectious cavity can be percutaneously drained. Management depends on the patient's condition and a tailored approach should always be offered. In the case of a patient who is young, has a good life expectancy, or in whom there is absence of significant comorbidities, a surgical attempt can be proposed. Surgical techniques favor, in terms of mortality, patency, and reinfection rate, the in situ reconstruction. Choice of technique relies on the center and the operator's experience. Long-term antibiotic therapy is always required in all cases, with close monitoring of the Creactive protein. 
Material and Methods
